Culbreath Katherine, Knell Jamie, Keefe Gregory, Han Sam M, Hong Charles R, Riley Heather B, Liu Enju, McAdam Alexander J, Modi Biren P, Jaksic Tom, Duggan Christopher P, Carey Alexandra N
From the Center for Advanced Intestinal Rehabilitation, Boston Children's Hospital, Boston, MA.
the Department of Surgery, Boston Children's Hospital and Harvard Medical School, Boston, MA.
J Pediatr Gastroenterol Nutr. 2022 Sep 1;75(3):345-350. doi: 10.1097/MPG.0000000000003501. Epub 2022 Jun 1.
To evaluate symptoms, enteral tolerance, growth, and antibiotic regimens in pediatric intestinal failure (IF) patients after treated with antibiotic therapy for small bowel bacterial overgrowth (SBBO).
Single-center retrospective review of children 0-18 years with IF with endoscopic cultures demonstrating >10 5 CFU/mL from 2010 to 2017. Symptoms, enteral tolerance, growth, and antibiotic regimens were evaluated at the time of endoscopy and 6 months later.
Of 505 patients followed in our intestinal rehabilitation program, 104 underwent upper gastrointestinal endoscopy and 78 had positive duodenal cultures. Clinical data pre- and post-endoscopy were available for 56 patients. Compared to baseline, in the 6 months following targeted antibiotic treatment, children showed significant improvement in emesis or feeding intolerance (58.9% vs 23.2%, P < 0.001), abdominal pain (16.1% vs 7.1%, P = 0.02), high stool output (42.9% vs 19.6%, P = 0.002), and gross GI bleeding (19.6% vs 3.6%, P = 0.003). Mean BMI-for-age z scores increased significantly (-0.03 ± 0.94 vs 0.27 ± 0.82, P = 0.03); however, height-for-age z scores, weight-for-age z scores, and percent of calories from enteral intake were not significantly different after therapy. Antibiotic regimens remained highly variable.
Children with IF and culture-positive SBBO showed significant improvement in symptoms and BMI-for-age z scores after duodenal culture with subsequent targeted antibiotic therapy. Longer follow-up may be needed to detect improvements in linear growth and percent of calories from enteral feeds. Antibiotic regimens remain highly variable. Long-term consequences of chronic antimicrobial therapy, including antimicrobial resistance, remain unknown. Prospective studies focused on standardizing duodenal sampling technique, correlating culture and pathology data, and evaluating antibiotic resistance patterns are needed.
评估小儿肠衰竭(IF)患者在接受小肠细菌过度生长(SBBO)抗生素治疗后的症状、肠内耐受性、生长情况及抗生素治疗方案。
对2010年至2017年年龄在0 - 18岁、IF且内镜培养显示每毫升菌落形成单位(CFU)>10⁵的儿童进行单中心回顾性研究。在内镜检查时及6个月后评估症状、肠内耐受性、生长情况及抗生素治疗方案。
在我们的肠道康复项目中随访的505例患者中,104例行上消化道内镜检查,78例十二指肠培养阳性。56例患者有内镜检查前后的临床数据。与基线相比,在针对性抗生素治疗后的6个月内,儿童在呕吐或喂养不耐受(58.9%对23.2%,P < 0.001)腹痛(16.1%对7.1%,P = 0.02)、高粪便输出量(42.9%对19.6%,P = 0.002)和胃肠道大出血(19.6%对3.6%,P = 0.003)方面有显著改善。平均年龄别BMI z评分显著增加(-0.03±0.94对0.27±0.82,P = 0.03);然而,治疗后年龄别身高z评分、年龄别体重z评分及肠内摄入热量百分比无显著差异。抗生素治疗方案仍高度可变。
IF且培养阳性的SBBO儿童在十二指肠培养及随后的针对性抗生素治疗后,症状及年龄别BMI z评分有显著改善。可能需要更长时间的随访以检测线性生长及肠内喂养热量百分比的改善情况。抗生素治疗方案仍高度可变。慢性抗菌治疗的长期后果,包括抗菌药物耐药性,仍不清楚。需要开展前瞻性研究以规范十二指肠采样技术、关联培养和病理数据并评估抗生素耐药模式。